Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 7, 2014, Pages 743-744

  Gomollon F ^a   Chowers, Y ^b   Danese, S ^c   Dignass, A ^d   Haagen Nielsen, O ^e   Lakatos, P L ^f   Lees, C W ^g   Lindgren, S ^h   Lukas, M ⁱ   Mantzaris, G J ^j   Michetti, P ^k   Moum, B ^l   Peyrin Biroulet, L ^m   Toruner, M ⁿ   Van Der Woude, J ^o   Weiss, G ^p   Stoevelaar, H ^q   Reinisch, W ^r  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b RAMBAM MEDICAL CENTER   (Israel)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d AGAPLESION MARKUS KRANKENHAUS   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g WESTERN GENERAL HOSPITAL   (United Kingdom)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j EVANGELISMOS HOSPITAL   (Greece)

^k UNIVERSITY OF LAUSANNE   (Switzerland)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY HOSPITAL OF NANCY   (France)

ⁿ ANKARA UNIVERSITY   (Turkey)

^o ERASMUS MEDICAL CENTER   (Netherlands)

^p INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^q Ismar Healthcare ^*  (Belgium)

^r MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

CHEMICAL COMPOSITION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERANCE; EVIDENCE BASED PRACTICE; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; DRUG HYPERSENSITIVITY; EUROPE; FEDERAL GOVERNMENT; HUMANS; IRON; IRRITABLE BOWEL SYNDROME;

EID: 84903365648     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12648     Document Type: Letter

References (7)

1. Reinisch W, Chowers Y, Danese S, et al,. The management of iron deficiency in inflammatory bowel disease-An online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013; 38: 1109-18.
2. Chertow GW, Winkelmayer WC,. On the relative safety of intravenous iron formulations: new answers, new questions. Am J Hematol 2010; 85: 643-4.
3. Toblli JE, Cao G, Oliveri L, Angerosa M,. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferriccarboxymaltose, iron sucrose and iron dextran in a non-clinical model. Arzneimittelforschung 2011; 61: 399-410.
4. Chertow GM, Mason PD, Vaage-Nilsen O, Ahmén J,. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-82.
5. Auerbach M, Coyne D, Ballard H,. Intravenous iron: from anathema to standard of care. Am J Hematol 2008; 83: 580-8.
6. Toblli JE, Cao G, Oliveri L, Angerosa M,. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 2012; 11: 66-78.
7. Gasche C, Berstad A, Befrits R, et al,. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545-53.